Effective Attenuation of Arteriosclerosis Following Lymphatic-Targeted Delivery of Hyaluronic Acid-Decorated Rapamycin Liposomes

References

• Virani Salim S, Alvaro A, Aparicio Hugo J, et al. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–e743. doi:10.1161/CIR.0000000000000950
   PubMed Web of Science ®Google Scholar
• Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386(9994):655–664. doi:10.1016/S0140-6736(15)60657-2
   PubMed Web of Science ®Google Scholar
• Samidurai A, Kukreja RC, Das A. Emerging role of mTOR signaling-related miRNAs in cardiovascular diseases. Oxid Med Cell Longev. 2018;2018(614902):1–23. doi:10.1155/2018/6141902
   Google Scholar
• Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016;37(22):1723–1732. doi:10.1093/eurheartj/ehv759
   PubMed Web of Science ®Google Scholar
• Razani B, Feng C, Coleman T, et al. Autophagy links inflammasomes to atherosclerotic progression. Cell Metab. 2012;15(4):534–544. doi:10.1016/j.cmet.2012.02.011
   PubMed Web of Science ®Google Scholar
• Lavandero S, Chiong M, Rothermel BA, Hill JA. Autophagy in cardiovascular biology. J Clin Invest. 2015;125(1):55–64. doi:10.1172/JCI73943
   PubMed Web of Science ®Google Scholar
• Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496(7446):445–455. doi:10.1038/nature12034
   PubMed Web of Science ®Google Scholar
• Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol. 2014;60(4):855–865. doi:10.1016/j.jhep.2013.11.031
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang F, Zou S, Qu L. Rapamycin: a bacteria-derived immunosuppressant that has anti-atherosclerotic effects and its clinical application. Front Pharmacol. 2019;9:1520.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. MTOR signaling in growth control and disease. Cell. 2012;149(2):274–293. doi:10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157. doi:10.1016/j.jconrel.2014.12.030
   PubMed Web of Science ®Google Scholar
• Mahapatra AK, Murthy PN, Chandana S, et al. Progress with liposomal drug delivery systems: formulation to therapy. Der Pharm Lett. 2017;6(3):110–128.
   Google Scholar
• Wang Y, Zhang K, Qin X, et al. Biomimetic nanotherapies: red blood cell based core-shell structured nanocomplexes for atherosclerosis management. Adv Sci. 2019;6(12):1900172. doi:10.1002/advs.201900172
   Web of Science ®Google Scholar
• Wang Y, Zhang K, Li T, et al. Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications. Theranostics. 2021;11(1):164–180. doi:10.7150/thno.47841
   PubMed Web of Science ®Google Scholar
• Boada C, Zinger A, Tsao C, et al. Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation. Circ Res. 2020;126(1):25–37. doi:10.1161/CIRCRESAHA.119.315185
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Nicholls SJ, Langsted A, et al. Advances in lipid-lowering therapy through gene-silencing technologies. Nat Rev Cardiol. 2018;15(5):261–272. doi:10.1038/nrcardio.2018.3
   PubMed Web of Science ®Google Scholar
• Rosborough BR, Raïch-Regué D, Matta BM, et al. Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood. 2013;121(18):3619–3630. doi:10.1182/blood-2012-08-448290
   PubMed Web of Science ®Google Scholar
• Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021;101(3):1371–1426. doi:10.1152/physrev.00026.2020
   PubMed Web of Science ®Google Scholar
• Liu Z, Fan Y, Zhang Z, et al. mTOR in the mechanisms of atherosclerosis and cardiovascular disease. Discov Med. 2021;31(164):129–140.
   PubMed Web of Science ®Google Scholar
• Sun JJ, Yin XW, Liu HH, et al. Rapamycin inhibits ox-LDL-induced inflammation in human endothelial cells in vitro by inhibiting the mTORC2/PKC/c-Fos pathway. Acta Pharmacol Sin. 2018;39(3):336–344. doi:10.1038/aps.2017.102
   PubMed Web of Science ®Google Scholar
• Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 2009;114(14):2926–2935. doi:10.1182/blood-2009-05-220889
   PubMed Web of Science ®Google Scholar
• Dou Y, Guo J, Chen Y, et al. Sustained delivery by a cyclodextrin material-based nanocarrier potentiates antiatherosclerotic activity of rapamycin via selectively inhibiting mTORC1 in mice. J Control Release. 2016;235:48–62. doi:10.1016/j.jconrel.2016.05.049
   PubMed Web of Science ®Google Scholar
• Lameijer MA, Tang J, Nahrendorf M, Beelen RH, Mulder WJ. Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease. Expert Rev Mol Diagn. 2013;13(6):567–580. doi:10.1586/14737159.2013.819216
   PubMed Web of Science ®Google Scholar
• Cicha I, Chauvierre C, Texier I, et al. From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovasc Res. 2018;114(13):1714–1727. doi:10.1093/cvr/cvy219
   PubMed Web of Science ®Google Scholar
• Chen W, Schilperoort M, Cao Y, Shi J, Tabas I, Tao W. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat Rev Cardiol. 2022;19(4):228–249. doi:10.1038/s41569-021-00629-x
   PubMed Web of Science ®Google Scholar
• Vaidyanathan K, Gopalakrishnan S. Nanomedicine in the diagnosis and treatment of atherosclerosis-a systematic review. Cardiovasc Hematol Disord Drug Targets. 2017;17(2):119–131. doi:10.2174/1871529X17666170918142653
   PubMedGoogle Scholar
• Hu B, Boakye-Yiadom KO, Yu W, et al. Nanomedicine approaches for advanced diagnosis and treatment of atherosclerosis and related ischemic diseases. Adv Healthc Mater. 2020;9(16):e2000336. doi:10.1002/adhm.202000336
   PubMed Web of Science ®Google Scholar
• Chan CKW, Zhang L, Cheng CK, et al. Recent advances in managing atherosclerosis via nanomedicine. Small. 2018;14(4):1702793. doi:10.1002/smll.201702793
   Web of Science ®Google Scholar
• Duivenvoorden R, Senders ML, van Leent MMT, et al. Nanoimmunotherapy to treat ischaemic heart disease. Nat Rev Cardiol. 2019;16(1):21–32. doi:10.1038/s41569-018-0073-1
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Nichols JW, Toh K, et al. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat Nanotechnol. 2016;11(6):533–538. doi:10.1038/nnano.2015.342
   PubMed Web of Science ®Google Scholar
• Tiantian Y, Wenji Z, Mingshuang S, et al. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting. Int J Pharm. 2014;471(1–2):245–257. doi:10.1016/j.ijpharm.2014.05.027
   PubMedGoogle Scholar
• Yan Z, Wang F, Wen Z, et al. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. J Control Release. 2012;157(1):118–125. doi:10.1016/j.jconrel.2011.07.034
   PubMed Web of Science ®Google Scholar
• Lei C, Liu XR, Chen QB, et al. Hyaluronic acid and albumin based nanoparticles for drug delivery. J Control Release. 2021;331:416–433. doi:10.1016/j.jconrel.2021.01.033
   PubMed Web of Science ®Google Scholar
• Tie S, Tan M. Current advances in multifunctional nanocarriers based on marine polysaccharides for colon delivery of food polyphenols. J Agric Food Chem. 2022;70(4):903–915. doi:10.1021/acs.jafc.1c05012
   PubMed Web of Science ®Google Scholar
• Yasin A, Ren Y, Li J, Sheng Y, Cao C, Zhang K. Advances in hyaluronic acid for biomedical applications. Front Bioeng Biotechnol. 2022;10:910290. doi:10.3389/fbioe.2022.910290
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045–2051. doi:10.1161/ATVBAHA.108.179705
   PubMed Web of Science ®Google Scholar
• Anker S, Asselbergs FW, Brobert G, Vardas P, Grobbee DE, Cronin M. Big data in cardiovascular disease. Eur Heart J. 2017;38(24):1863–1865. doi:10.1093/eurheartj/ehx283
   PubMed Web of Science ®Google Scholar
• Yang X, Wang L, Zeng H, Dubey L, Zhou N, Pu J. Effects of simvastatin on NF-kappaB-DNA binding activity and monocyte chemoattractant protein-1 expression in a rabbit model of atherosclerosis. J Huazhong Univ Sci Technol Med Sci. 2006;26(2):194–198. doi:10.1007/BF02895814
   PubMedGoogle Scholar
• Wiig H, Swartz MA. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev. 2012;92(3):1005–1060. doi:10.1152/physrev.00037.2011
   PubMed Web of Science ®Google Scholar
• Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315–327. doi:10.1161/CIRCRESAHA.118.313591
   PubMed Web of Science ®Google Scholar
• Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692–702. doi:10.1161/CIRCRESAHA.115.306361
   PubMed Web of Science ®Google Scholar
• Aspelund A, Robciuc MR, Karaman S, Makinen T, Alitalo K. Lymphatic system in cardiovascular medicine. Circ Res. 2016;118(3):515–530. doi:10.1161/CIRCRESAHA.115.306544
   PubMed Web of Science ®Google Scholar
• Vengrenyuk Y, Nishi H, Long X, et al. Cholesterol loading reprograms the microRNA-143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. Arterioscler Thromb Vasc Biol. 2015;35(3):535–546. doi:10.1161/ATVBAHA.114.304029
   PubMed Web of Science ®Google Scholar
• Vieira JM, Norman S, Villa Del Campo C, et al. The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. J Clin Invest. 2018;128(8):3402–3412. doi:10.1172/JCI97192
   PubMed Web of Science ®Google Scholar
• Jiang G, Park K, Kim J, et al. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers. 2008;89(7):635–642. doi:10.1002/bip.20978
   PubMed Web of Science ®Google Scholar
• Dey A, Koli U, Dandekar P, Jain R. Investigating behavior of polymers in nanoparticles of chitosan oligosaccharides coated with hyaluronic acid. Polymer. 2016;93:44–52. doi:10.1016/j.polymer.2016.04.027
   Web of Science ®Google Scholar
• Jiang DH, Liang JR, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 2011;91(1):221–264. doi:10.1152/physrev.00052.2009
   PubMed Web of Science ®Google Scholar
• Yang Z, Tian R, Wu J, et al. Impact of semiconducting perylene diimide nanoparticle size on lymph node mapping and cancer imaging. ACS Nano. 2017;11(4):4247–4255. doi:10.1021/acsnano.7b01261
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T, Poh MZ, Insin N, et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J. 2010;99(5):1342–1349. doi:10.1016/j.bpj.2010.06.016
   PubMed Web of Science ®Google Scholar
• Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011;22(4):189–195. doi:10.1016/j.cytogfr.2011.10.001
   PubMed Web of Science ®Google Scholar
• Vinchi F, Porto G, Simmelbauer A, et al. Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction. Eur Heart J. 2020;41(28):2681–2695. doi:10.1093/eurheartj/ehz112
   PubMed Web of Science ®Google Scholar
• Carmona-Rivera C, Zhao W, Yalavarthi S, Kaplan MJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis. 2015;74(7):1417–1424. doi:10.1136/annrheumdis-2013-204837
   PubMed Web of Science ®Google Scholar